We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trental & Vitamin E for Radiation-Induced Fibrosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00583700
First Posted: December 31, 2007
Last Update Posted: January 29, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Iowa
December 20, 2007
December 31, 2007
October 18, 2012
January 29, 2013
January 29, 2013
February 2003
May 2010   (Final data collection date for primary outcome measure)
Subjective, Objective, Management, and Analytic (SOMA) Score [ Time Frame: 18 month post-treatment ]
A primary outcome of interest is the composite Subjective, Objective, Management, and Analytic (SOMA) score at 18-month follow-up visit. Maximum score is 45, with a score of 0 being ideal and representing no treatment-related side effects at the study visit.
The primary outcome of interest is composite SOMA score at 18-month follow-up visit [ Time Frame: 18 month post-treatment ]
Complete list of historical versions of study NCT00583700 on ClinicalTrials.gov Archive Site
Tissue Compliance [ Time Frame: 18 months post-treatment ]

Tissue compliance meter measurements of the treated breast compared to the non-treated breast were obtained at 18 months post-radiation therapy. Tissue compliance simply means how soft and pliable the breast tissue is when force is applied to it.

One physician would hold the tissue compliance meter (TCM) against the participant's skin. A standard amount of force would be applied. A second physician would read the displacement scale for a specific set of areas on the breast. The range of the scale was 0 to 60 milimeters (mm). The physician's were blineded to the participant's intervention at the time of measurement.

The final value is the difference between the untreated and the treated breast [untreated - treated]. The range of these differences was -3.3 to 7.0 mm.

Tissue compliance of the treated breast compared to the non-treated breast [ Time Frame: 12 and 18 months post-treatment ]
Not Provided
Not Provided
 
Trental & Vitamin E for Radiation-Induced Fibrosis
Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study
This study seeks to determine if a combination of Trental and Vitamin E prevents the development of radiation fibrosis in women treated with radiation for the definitive management of their breast cancer.

Radiation fibrosis occurs in approximately 25% of those women treated with radiation for breast cancer. Of these, approximately 3 to 5% will develop into an acute, painful form of fibrosis. Mild fibrosis can present as a thicker or more dense breast where the acute form can cause pain in the breast, significant hardening, and inflammation.

Treatments for fibrosis are lacking, with the primary treatment being hyperbaric oxygen therapy. The combination of Trental & Vitamin E has been used with success in Europe and at the University of Iowa.

The focus of this study is to prevent fibrosis through intervention with Trental & Vitamin E. The study has two arms, a control arm and an intervention arm. The study is not blinded. Measurements are taken at standard follow-up visits to measure breast density and lymphedema.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Fibrosis
  • Drug: Pentoxifylline
    Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
    Other Name: Trental
  • Drug: Vitamin E
    Vitamin E (Over-the-counter) 400 I.U. once daily
  • No Intervention: 1
    Control for study - watchful waiting.
  • Experimental: 2
    Combined treatment with Pentoxifylline and Vitamin E.
    Interventions:
    • Drug: Pentoxifylline
    • Drug: Vitamin E

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
54
June 2012
May 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with histologically documented cancer of the breast or DCIS or head and neck referred for definitive radiation with curative intent.
  • No evidence of metastatic disease.
  • Minimum life expectancy of at least 12 months.
  • Aged greater than 20 years.
  • If female, pregnancy excluded.
  • No documented history of collagen vascular disease.

Exclusion Criteria:

  • Cognitively impaired patients
  • Prisoners
  • No histology available
  • Documented metastatic disease
  • Allergy to Trental
  • Life expectance of less than 12 months.
  • Aged less than 20 years
  • Collagen vascular disease present
  • Pregnant
  • History of liver disease
  • Use of anticoagulants
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00583700
200211003
Yes
Not Provided
Not Provided
University of Iowa
University of Iowa
Not Provided
Principal Investigator: Geraldine Jacobson, MD MPH department of radiation oncology
University of Iowa
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top